BR9911324A - Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal - Google Patents

Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal

Info

Publication number
BR9911324A
BR9911324A BR9911324-4A BR9911324A BR9911324A BR 9911324 A BR9911324 A BR 9911324A BR 9911324 A BR9911324 A BR 9911324A BR 9911324 A BR9911324 A BR 9911324A
Authority
BR
Brazil
Prior art keywords
fragility
compositions
ghs
serm
modulators
Prior art date
Application number
BR9911324-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9911324A publication Critical patent/BR9911324A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9911324-4A 1998-06-16 1999-06-16 Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal BR9911324A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16
PCT/IB1999/001117 WO1999065486A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
BR9911324A true BR9911324A (pt) 2001-04-03

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911324-4A BR9911324A (pt) 1998-06-16 1999-06-16 Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal

Country Status (30)

Country Link
EP (1) EP1087764A1 (no)
JP (1) JP2002518326A (no)
KR (1) KR20010052852A (no)
CN (1) CN1301160A (no)
AP (1) AP9901582A0 (no)
AR (1) AR018869A1 (no)
AU (1) AU4054799A (no)
BG (1) BG105041A (no)
BR (1) BR9911324A (no)
CA (1) CA2335134A1 (no)
CO (1) CO5070587A1 (no)
EA (1) EA200001186A1 (no)
GT (1) GT199900087A (no)
HN (1) HN1999000097A (no)
HR (1) HRP20000859A2 (no)
HU (1) HUP0102505A3 (no)
ID (1) ID27599A (no)
IL (1) IL138630A0 (no)
IS (1) IS5691A (no)
MA (1) MA26652A1 (no)
NO (1) NO20006312L (no)
OA (1) OA11505A (no)
PA (1) PA8475901A1 (no)
PE (1) PE20000646A1 (no)
PL (1) PL344981A1 (no)
SK (1) SK18912000A3 (no)
TN (1) TNSN99124A1 (no)
TR (1) TR200003544T2 (no)
WO (1) WO1999065486A1 (no)
ZA (1) ZA993975B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047735A2 (en) * 1999-02-08 2000-08-17 Mcgill University NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR ERRalpha
ES2274854T3 (es) 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
JP2004507502A (ja) 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク 成長ホルモン分泌促進物質のための徐放性製剤
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
ID27599A (id) 2001-04-12
CO5070587A1 (es) 2001-08-28
JP2002518326A (ja) 2002-06-25
NO20006312D0 (no) 2000-12-12
OA11505A (en) 2004-05-07
ZA993975B (en) 2000-12-15
PL344981A1 (en) 2001-11-19
HUP0102505A3 (en) 2002-12-28
HRP20000859A2 (en) 2001-04-30
GT199900087A (es) 2000-12-07
TNSN99124A1 (fr) 2005-11-10
TR200003544T2 (tr) 2001-04-20
KR20010052852A (ko) 2001-06-25
NO20006312L (no) 2000-12-12
PE20000646A1 (es) 2000-08-05
CN1301160A (zh) 2001-06-27
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
CA2335134A1 (en) 1999-12-23
AR018869A1 (es) 2001-12-12
EP1087764A1 (en) 2001-04-04
BG105041A (en) 2001-08-31
MA26652A1 (fr) 2004-12-20
SK18912000A3 (sk) 2001-10-08
AP9901582A0 (en) 1999-06-30
EA200001186A1 (ru) 2001-06-25
PA8475901A1 (es) 2000-05-24
WO1999065486A1 (en) 1999-12-23
IS5691A (is) 2000-10-27
AU4054799A (en) 2000-01-05
HN1999000097A (es) 1999-11-03

Similar Documents

Publication Publication Date Title
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
EP0911321A3 (en) Compounds for the treatment of osteoporosis
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0100558A (pt) Composições e métodos para tratar a osteoporose
PT1222195E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
AP9801269A0 (en) Prostaglandin agonists.
BR9911324A (pt) Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal
BR9911228A (pt) Combinações terapêuticas compreendendo um modulador seletivo de um receptor de estrogênio e hormÈnio paratireóide
BR9911357A (pt) Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal
BR9908214A (pt) Tratamento para linfomas foliculares utilizando inibidores da via da linfotoxina (lt)
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
BR9814403A (pt) "derivados do indol úteis para o tratamento, entre outros, de osteoporose"
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol
IL124828A0 (en) Hyaluronic acid receptors binding agents and the use thereof
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
TH57984A3 (th) การรวมในทางการรักษาซี่งประกอบด้วยตัวปรับตัวรับเอสโตรเจนแบบคัดเลือกและฮอร์โมนพาราไธรอยด์

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]